You can buy or sell ACRS and other stocks, options, ETFs, and crypto commission-free!
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments. Read More The Dermatology Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
52 Week High
52 Week Low
Yahoo FinanceMay 16
Aclaris Therapeutics, Inc. Q1 2019 Earnings Call Transcript
Logo of jester cap with thought bubble with words 'Fool Transcripts' below it Image source: The Motley Fool. Aclaris Therapeutics (NASDAQ: ACRS) Q1 2019 Earnings Call May 8, 2019, 2:00 p.m. ET Scroll to continue with content Ad Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen and welcome to the first quarter 2019 Aclaris Therapeutics Inc. earnings conference call. At this time, all participants are in a listen-only mode....
Yahoo FinanceMay 8
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 8
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
Submitted IND for ATI-450, an oral MK2 inhibitor RHOFADE net sales of $3.7 million for the first quarter of 2019 Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced its financial results for the first quarter of 2019, and provided an update on its clinical development and commercial programs. Highlights: ...
Expected Aug 2, After Hours